Identifier |
20170403_nanos_sciplatform1_01-abstract |
Title |
Tocilizumab in Patients With Giant Cell Arteritis: Results From a Phase 3 Randomized Controlled Trial (abstract) |
Creator |
Susan Mollan; Katie Tuckwell; Sophie Dimonaco; Micki Klearman; Neil Collinson; John Stone |
Affiliation |
(SM) University Hospitals Birmingham NHS Trust, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham B15 2GW, United Kingdom; (KT) (SD) (NC) Roche Products Ltd., Welwyn Garden City, United Kingdom; (MK) Genentech, South San Francisco, California; (JS) Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, Massachusetts |
Subject |
Vascular Disorders; Neuro-ophth & Systyemic Disease (eg. MS, MG, Thyroid); Optic neuropathy |
Description |
The efficacy and safety of tocilizumab (TCZ), an IL-6 receptor-alpha inhibitor, was evaluated in patients with giant cell arteritis (GCA) in GiACTA, a randomized, double-blind, placebo-controlled trial.1 Data for week 52 outcome measures are presented. |
Date |
2017 |
Language |
eng |
Format |
application/pdf |
Type |
Text |
Source |
2017 North American Neuro-Ophthalmology Society Annual Meeting |
Relation is Part of |
NANOS Annual Meeting 2017: Scientific Platform I |
Collection |
Neuro-Ophthalmology Virtual Education Library: NANOS Annual Meeting Collection: https://novel.utah.edu/collection/nanos-annual-meeting-collection/ |
Publisher |
North American Neuro-Ophthalmology Society |
Holding Institution |
Spencer S. Eccles Health Sciences Library, University of Utah |
Rights Management |
Copyright 2013. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright |
ARK |
ark:/87278/s67x067m |
Setname |
ehsl_novel_nam |
ID |
1273002 |
Reference URL |
https://collections.lib.utah.edu/ark:/87278/s67x067m |